Low-Molecular-Weight Heparin (Dalteparin) Demonstrated a Weaker Effect on Rat Bone Metabolism Compared with Heparin
スポンサーリンク
概要
- 論文の詳細を見る
- Japanese Pharmacological Societyの論文
- 1997-05-01
著者
-
Nishijima Masahiko
Central Research Laboratories Kissei Pharmaceutical Co. Ltd.
-
Itoh Fumiaki
Central Research Laboratories Kissei Pharmaceutical Co. Ltd.
-
UJIIE Arao
Central Research Laboratories, Kissei Pharmaceutical Co., Ltd.
-
Ujiie Arao
Central Research Laboratories Kissei Pharmaceutical Co. Ltd.
-
Nishiyama Masahiko
Central Research Laboratories, Kissei Pharmaceutical Co., Ltd.
関連論文
- A Rapid- and Short-Acting Hypoglycemic Agent KAD-1229 Improves Post-Prandial Hyperglycemia and Diabetic Complications in Streptozotocin-Induced Non-Insulin-Dependent Diabetes Mellitus Rats
- Low-Molecular-Weight Heparin (Dalteparin) Demonstrated a Weaker Effect on Rat Bone Metabolism Compared with Heparin
- Treatment effects of bisphosphonates on ovariectomy-induced osteopenia in rats: Comparison between clodronate and etidronate
- Dopamine Receptor Affinities in Vitro and Stereotypic Activities in Vivo of Cabergoline in Rats
- CANINE CORONARY REPERFUSION MODEL AND THE INFLUENCE OF OKY-046, A SPECIFIC TXA_2 SYNTHETASE INHIBITOR : Ischemic Heart Disease (II), Coronary Circulation : II : 48 Annual Scientific Meeting, Japanese Circulation Society
- Effects of KCA-012 on Bone Metabolism in Organ Culture
- Mechanism f inhibitory action of tranilast on the release of slow reacting substance of anaphylaxis (SRS-A) in vitro: Effect of tranilast on the release of arachidonic acid and its metabolites.
- Study of the mechanism of inhibitory action of tranilast on chemical mediator release.
- Enzymatic study to characterize the slow reacting substance of anaphylaxis (SRS-A) and leukotrienes.
- Beneficial effect of OKY-046, a selective thromboxane A2 synthetase inhibitor, on experimental cerebral vasospasm.
- Effects of KCA-098 on Bone Metabolism: Comparison with Those of Ipriflavone.
- Pharmacological studies on the TXA2 synthetase inhibitor (E)-3-(p-(1H-imidazol-1-ylmethyl)phenyl)-2-propenoic acid (OKY-046).